A candidate precursor to serous carcinoma that originates in the distal fallopian tube
暂无分享,去创建一个
J. Garber | F. McKeon | D. Cramer | M. Nucci | C. Crum | A. Miron | F. Medeiros | Yonghee Lee | F. McKeon | C. Crum | A. Saleemuddin | C. Birch | R. Drapkin | Y. Lee | R. Drapkin | H. Mou | RW Gordon | DW Cramer | R. W. Gordon | R. Gordon | H. Mou | Felipe A. Medeiros | Aasia Saleemuddin
[1] R. Berkowitz,et al. Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.
[2] Christopher P Crum,et al. The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.
[3] A. Monteiro,et al. DNA damage response: Determining the fate of phosphorylated histone H2AX , 2006, Cancer biology & therapy.
[4] Sadir J Alrawi,et al. Aberrant crypt foci. , 2006, Anticancer research.
[5] B. Karlan,et al. BRCA-Mutation–Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? , 2005, Obstetrics and gynecology.
[6] C. Mettlin,et al. Age-specific ovarian cancer incidence rate patterns in the United States. , 2005, Gynecologic oncology.
[7] L. Latonen,et al. Cellular UV damage responses--functions of tumor suppressor p53. , 2005, Biochimica et biophysica acta.
[8] J. Hayes,et al. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. , 2005, Molecular cell.
[9] A. Strasser,et al. Death squads enlisted by the tumour suppressor p53. , 2005, Biochemical and biophysical research communications.
[10] D. Bell,et al. Current issues in the pathology of ovarian cancer. , 2005, The Journal of reproductive medicine.
[11] Ming Yang,et al. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer. , 2005, Cancer letters.
[12] T. Ørntoft,et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.
[13] Dimitris Kletsas,et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.
[14] L. Cope,et al. Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.
[15] Michel Nussenzweig,et al. H2AX: the histone guardian of the genome. , 2004, DNA repair.
[16] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[17] J. Boyd,et al. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. , 2004, Gynecologic oncology.
[18] B. Bender,et al. Adenocarcinoma of the fallopian tube , 2004, Virchows Archiv A.
[19] B. Stewart,et al. World Cancer Report , 2003 .
[20] R. Bast,et al. Prevention of ovarian cancer: intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] W. Murdoch,et al. Ovulation-Induced DNA Damage in Ovarian Surface Epithelial Cells of Ewes: Prospective Regulatory Mechanisms of Repair/Survival and Apoptosis1 , 2001, Biology of reproduction.
[22] P. V. van Diest,et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.
[23] B. Rosen,et al. Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.
[24] K. Offit,et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.
[25] F. Pontén,et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. , 1999, The American journal of pathology.
[26] J. Southgate,et al. Application of a marker of ciliated epithelial cells to gynaecological pathology. , 1999, Journal of clinical pathology.
[27] J. Southgate,et al. Induction of a differentiated ciliated cell phenotype in primary cultures of Fallopian tube epithelium. , 1998, Human reproduction.
[28] F. Pontén,et al. Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. , 1997, The American journal of pathology.
[29] M. Wells,et al. p53 protein expression in putative precursor lesions of epithelial ovarian cancer , 1995, Histopathology.
[30] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[31] R. Scully,et al. Early de novo ovarian carcinoma. A study of fourteen cases , 1994, Cancer.
[32] M. McKay,et al. Cancer of the ovary. , 1994, The New England journal of medicine.
[33] J. Bartek,et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.
[34] J. Gerdes,et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. , 1991, The American journal of pathology.
[35] M. Friedlander,et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases , 1989, Cancer.
[36] T. Fredrickson. Ovarian tumors of the hen. , 1987, Environmental health perspectives.